---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-23-000051"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T14:40:28.165190+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics Q2 2023 net loss $5.6M ($0.07/shr); R&D spend up on cadisegliatin; Nasdaq extension granted

## Summary
- Net loss of $5.6M ($0.07 per share) vs $3.2M ($0.04) in Q2 2022; no quarterly revenue.
- R&D expenses $4.7M, up 113% from $2.2M, driven by cadisegliatin drug product costs.
- Cash $12.6M at June 30, 2023, up modestly from $12.1M at Dec 31, 2022.
- Nasdaq extended deadline to regain $1 bid compliance to Dec 18, 2023 (granted July 17).
- Phase 3 study for cadisegliatin (TTP399) expected to initiate by year-end 2023.

## SEC filing metadata
- accession: 0001641489-23-000051
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000051/0001641489-23-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000051/vtvt-20230811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-23-000051
- JSON: https://secwatch.observer/filing/0001641489-23-000051.json
- Plain text: https://secwatch.observer/filing/0001641489-23-000051.txt

## Key facts
- Earnings Releases
  vTv Therapeutics Inc. reported financial results for second quarter ended June 30, 2023.
  - Period: second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 11, 2023, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641489/000164148923000051/0001641489-23-000051-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.